For years, "AI in pharma" meant dashboards, predictive alerts, and smarter ways to visualise serialisation data. Useful? Yes. Transformative? Not quite. The conversation has changed.

Agentic AI - systems capable of reasoning, planning, executing multi-step tasks, and adapting mid-action without human prompting - is now entering pharmaceutical operations in earnest. Not as a pilot, and not as a single-point automation tool, but as an operational layer capable of reshaping how drug manufacturers run quality, supply chain, compliance, and pharmacovigilance functions end to end.

This is not about replacing track-and-trace. It's about what becomes possible when the intelligence operating across your supply chain stops waiting to be asked.

From Compliance Tool to Operational Intelligence

Track-and-trace was always a means to an end. The EU Falsified Medicines Directive (FMD) and the US Drug Supply Chain Security Act (DSCSA) forced pharmaceutical companies to build serialisation infrastructure and item-level visibility. The data was always there. What was missing was the capacity to act on it dynamically.

Agentic AI changes this equation. Rather than surfacing a flag for a human to investigate, an agent can investigate autonomously - cross-referencing batch records, pulling environmental monitoring logs, checking equipment maintenance history, and producing a documented root cause analysis in hours rather than weeks. In a regulated industry where deviation investigations routinely consume days of skilled resource, this is not a minor efficiency gain. It is a structural change to how quality operations function.

The same serialisation infrastructure that was built for regulatory compliance becomes, in an agentic environment, the data backbone for autonomous operations - inventory optimisation, supplier switching, rerouting, and demand forecasting - all executing in real time.

Where Agentic AI Is Creating Measurable Value in Pharma Operations

1. Supply Chain Orchestration

Traditional pharmaceutical supply chains are managed reactively. An alert fires, someone investigates, a decision is made. The cycle is slow, and in a sector where a missed delivery or a production shortfall has direct patient consequences, slow is expensive.

Agentic systems change this to a proactive, continuous model. Agents monitor order statuses, flag lead time deviations, identify at-risk suppliers, and - critically - propose and execute corrective actions: reordering from alternate suppliers, adjusting distribution schedules, rerouting deliveries. Industry platforms like TraceLink are already building "Agentic Orchestration" capabilities explicitly designed around this model, with AI agents that monitor and resolve exceptions across the end-to-end supply chain in real time.

The serialisation and traceability data that companies invested heavily in building for FMD and DSCSA compliance now serves a second, more commercially valuable function: it is the real-time operational signal that agentic supply chain systems run on.

2. Manufacturing Quality and Deviation Management

If there is one area where agentic AI is gaining the fastest traction in pharma, it is manufacturing quality. The reason is structural: quality workflows are procedural, well-documented, and governed by logic that agents can learn and execute. And the labour intensity is significant, making the return on investment straightforward to quantify.

Deviation investigation is the standout use case. In conventional pharmaceutical manufacturing, a single deviation can trigger an investigation process lasting days or weeks - pulling in quality engineers, production records, equipment logs, and regulatory documentation. An agentic system can complete the same investigation in a fraction of the time, with full audit trail, by drawing autonomously across integrated data sources.

Beyond deviations, agents are being applied to change control workflows, CAPA (Corrective and Preventive Action) management, and environmental monitoring - areas that share the same combination of procedural complexity and documentation burden that makes agentic automation highly effective.

3. Pharmacovigilance

Drug safety monitoring has long been one of the most resource-intensive functions in pharmaceutical operations. The volume of adverse event reports, the multilingual nature of global safety data, and the regulatory requirements for case processing create a workflow problem that traditional automation only partially addresses.

Agentic AI is reclaiming significant capacity here. Systems can now receive a safety report - via phone, email, or digital submission - translate it, extract the four minimum regulatory elements (identifiable reporter, identifiable patient, adverse reaction, suspect product), and process it into the required format without human involvement in the routine steps. More sophisticated agents are being deployed for signal detection, literature monitoring, and duplicate case identification across global safety databases.

The IQVIA "Vigilance Detect" platform is one example of where this is already operational at scale, with agentic systems reclaiming up to 40% of pharmacovigilance team capacity that was previously consumed by administrative processing - freeing safety scientists for the analysis and clinical judgement that genuinely requires them.

4. Regulatory Affairs and Submissions

Regulatory submissions - INDs, NDAs, BLAs, CTD dossiers - are among the most documentation-heavy processes in any industry. They require gathering, formatting, cross-referencing, and validating data from dozens of internal systems, then assembling it into formats that satisfy agency requirements.

Agentic AI is already compressing timelines meaningfully here. AI-assisted clinical study report authoring has been cited as delivering up to 40% faster turnaround in some implementations. More broadly, agents are being used to monitor evolving regulatory requirements (the pace of change from eCTD 3.x to 4.0, ePI rollouts, and UDI requirements is significant), flag compliance gaps, and prepare submission-ready documentation packages with reduced manual effort.

The FDA's own recent deployment of an agency-wide agentic AI platform - designed to support regulatory reviews, surveillance, and inspections - signals that the regulators themselves are embedding this technology, which will in turn shape expectations for how submissions are structured and how quickly reviews proceed.

The Governance Challenge No One Should Underestimate

The case for agentic AI in pharmaceutical operations is strong. But the sector's regulatory context means governance is not an afterthought - it is a precondition for deployment.

The EU AI Act, now in active enforcement, creates a risk-based classification framework that will place many pharmaceutical AI applications in the high-risk category. This means requirements for risk management documentation, data governance frameworks, transparency, and human oversight that go considerably beyond what most organisations have in place for conventional software.

The FDA's January 2025 guidance makes the position clear: AI must support regulatory decisions without replacing human judgement. This "human-on-the-loop" model - where agents do the heavy lifting but qualified personnel certify outcomes - is not a temporary concession to regulatory caution. It is likely the operating model for the foreseeable future, and organisations designing agentic implementations should build for it from the start rather than retrofitting oversight after the fact.

Validation is the other major consideration. Pharmaceutical manufacturing operates under GMP frameworks that require software to be validated before use in production processes. Agentic systems - which adapt and learn - present validation challenges that the industry is still working through. The CIOMS XIV framework on AI in pharmacovigilance, published in 2025, is one signal of where standard-setting is heading, but organisations deploying agentic AI today are largely operating ahead of fully settled guidance.

None of this is a reason to wait. But it is a reason to approach deployment with clear governance architectures, explainability requirements, and audit trail capabilities built into the system design.

Why More Than Half of Pharma Is Still Hesitating

Despite the momentum, a Pistoia Alliance survey conducted in early 2025 found that more than half of pharmaceutical companies were still resisting meaningful agentic AI adoption. The barriers are real: validated systems are difficult to change, data quality is often insufficient, and cultural resistance to autonomous decision-making in a patient-safety context is legitimate.

There is also the failure rate question. Across life sciences generally, over 40% of agentic AI initiatives are projected to be cancelled before reaching production - not because the technology fails, but because implementations are not anchored in clear business value, governance frameworks are absent, or change management is underestimated. The companies that will benefit most are not necessarily those who move fastest. They are those who move with the most operational clarity: specific use cases, measurable outcomes, and integration into existing validated systems rather than parallel deployments that create new data silos.

The Strategic Framing for Pharma Operations Leaders

The question for pharmaceutical operations leaders in 2026 is not whether agentic AI will become part of their operational model - it will. The question is what position their organisation wants to be in when the majority of the market catches up.

McKinsey estimates that 75 to 85 percent of pharmaceutical workflows can be enhanced or automated by AI agents. Clinical development productivity is forecast to improve by 35 to 45 percent over five years with agentic systems embedded across the function. The AI in pharma market is projected to grow from approximately $1.9 billion in 2025 to over $16 billion by 2034.

These numbers matter less than the operational reality they represent: the companies building agentic capabilities now - in quality, supply chain, pharmacovigilance, and regulatory affairs - are compressing timelines, reducing cost, and improving compliance in ways their slower-moving competitors are not. The serialisation and traceability infrastructure built for regulatory compliance is not a sunk cost. In an agentic operating environment, it is a strategic asset. The data it generates is exactly what autonomous agents need to function - and it is already there.

How VE3 Supports Pharmaceutical Operations Transformation

VE3 works with pharmaceutical and life sciences organisations on the enterprise AI and data infrastructure decisions that determine whether agentic deployments succeed or stall. That means connecting legacy manufacturing and supply chain systems to the data architectures that agents require, building governance frameworks that satisfy regulatory requirements while enabling meaningful autonomy, and designing human-on-the-loop oversight models that are operationally practical rather than theoretical.

The transition from track-and-trace compliance to agentic operations intelligence is not a technology problem. It is an integration, governance, and change management problem - and it is one that requires expertise across the full stack, from data engineering to regulatory affairs.

If your organisation is evaluating where agentic AI fits into your operations roadmap, we'd welcome the conversation. Get in touch with us now.